Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells

Cell Death and Differentiation

Volumn 18, Issue 6, 2011, Pages 1024-1035

  Trisciuoglio, D ^a   Gabellini, C ^a,b   Desideri, M ^a   Ragazzoni, Y ^a   De Luca, T ^a   Ziparo, E ^b   Del Bufalo, D ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

bcl 2; BH domain; cancer; HIF 1; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; POTASSIUM BOROHYDRIDE; PROTEIN BCL 2; VASCULOTROPIN;

ARTICLE; COLON CARCINOMA; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIC CELL; LUNG CARCINOMA; MELANOMA CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; TRANSCRIPTION REGULATION; UBIQUITINATION;

CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MUTATION; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION, GENETIC; UBIQUITINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955805684     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2010.175     Document Type: Article

References (36)

1. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656. (Pubitemid 37328916)
2. Kvansakul M, Yang H, Fairlie WD, Czabotar PE, Fischer SF, Perugini MA et al. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ 2008; 15: 1564-1571.
3. Shibasaki F, Kondo E, Akagi T, McKeon F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 1997; 386: 728-731. (Pubitemid 27193495)
4. de Moissac D, Zheng H, Kirshenbaum LA. Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappaB signaling pathway for suppression of apoptosis. J Biol Chem 1999; 274: 29505-29509.
5. Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M. Bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int J Cancer 2000; 86: 188-196. (Pubitemid 30180813)
6. Huang DC, Adams JM, Cory S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J 1998; 17: 1029-1039. (Pubitemid 28077657)
7. Hunter JJ, Bond BL, Parslow TG. Functional dissection of the human Bcl-2 protein: sequence requirements for inhibition of apoptosis. Mol Cell Biol 1996; 16: 877-883.
8. Trisciuoglio D, Desideri M, Ciuffreda L, Mottolese M, Ribatti D, Vacca A et al. Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol 2005; 205: 414-421. (Pubitemid 41598856)
9. Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G et al. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 2002; 16: 1453-1455.
10. Giorgini S, Trisciuoglio D, Gabellini C, Desideri M, Castellini L, Colarossi C et al. Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Mol Cancer Res 2007; 5: 761-771. (Pubitemid 47294804)
11. Biroccio A, Candiloro A, Mottolese M, Sapora O, Albini A, Zupi G et al. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J 2000; 14: 652-660. (Pubitemid 30198564)
12. Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T et al. Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res 2005; 65: 5063-5069. (Pubitemid 40827314)
13. Diensthuber M, Potinius M, Rodt T, Stan AC, Welkoborsky HJ, Samii M et al. Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma. J Neurooncol 2008; 89: 131-139.
14. Warner KA, Miyazawa M, Cordeiro MM, Love WJ, Pinsky MS, Neiva KG et al. Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia 2008; 10: 131-139. (Pubitemid 351240879)
15. Gabellini C, Castellini L, Trisciuoglio D, Kracht M, Zupi G, Del Bufalo D. Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma. J Neurochem 2008; 107: 871-882.
16. Fernandez A, Udagawa T, Schwesinger C, Beecken W, Chilles-Gerte E, McDonnell T et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001; 93: 208-213. (Pubitemid 32166491)
17. Del Bufalo D, Trisciuoglio D, Scarsella M, Zangemeister-Wittke U, Zupi G. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 2003; 22: 8441-8447. (Pubitemid 37523896)
18. Zeitlin BD, Joo E, Dong Z, Warner K, Wang G, Nikolovska-Coleska Z et al. Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res 2006; 66: 8698-8706. (Pubitemid 44449186)
19. Anai S, Shiverick K, Medrano T, Nakamura K, Goodison S, Brown BD et al. Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization. Urology 2007; 70: 832-837. (Pubitemid 350030244)
20. Kaneko T, Zhang Z, Mantellini MG, Karl E, Zeitlin B, Verhaegen M et al. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res 2007; 67: 9685-9693. (Pubitemid 47621215)
21. Trisciuoglio D, Gabellini C, Desideri M, Ziparo E, Zupi G, Del Bufalo D. Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PloS One 2010; 5: e11772.
22. Kawatani M, Imoto M. Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion. J Biol Chem 2003; 278: 19732-19742. (Pubitemid 36799159)
23. Lee LC, Hunter JJ, Mujeeb A, Turck C, Parslow TG. Evidence for alpha-helical conformation of an essential N-terminal region in the human Bcl2 protein. J Biol Chem 1996; 271: 23284-23288. (Pubitemid 26314770)
24. Shimizu S, Konishi A, Kodama T, Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc Natl Acad Sci USA 2000; 97: 3100-3105. (Pubitemid 30183262)
25. Hotchkiss RS, McConnell KW, Bullok K, Davis CG, Chang KC, Schwulst SJ et al. TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol 2006; 176: 5471-5477.
26. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336. (Pubitemid 120029101)
27. O'Connell J, Bennett MW, Nally K, O'Sullivan GC, Collins JK, Shanahan F. Interferon-gamma sensitizes colonic epithelial cell lines to physiological and therapeutic inducers of colonocyte apoptosis. J Cell Physiol 2000; 185: 331-338.
28. Wang Q, Gao F, May WS, Zhang Y, Flagg T, Deng X. Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway. Mol Cell 2008; 29: 488-498. (Pubitemid 351282542)
29. Denis GV, Yu Q, Ma P, Deeds L, Faller DV, Chen CY. Bcl-2, via its BH4 domain, blocks apoptotic signaling mediated by mitochondrial Ras. J Biol Chem 2003; 278: 5775-5785. (Pubitemid 36800823)
30. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-638. (Pubitemid 26386937)
31. Jin Z, May WS, Gao F, Flagg T, Deng X. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J Biol Chem 2006; 281: 14446-14456. (Pubitemid 43848375)
32. Kang CB, Tai J, Chia J, Yoon HS. The flexible loop of Bcl-2 is required for molecular interaction with immunosuppressant FK-506 binding protein 38 (FKBP38). FEBS Lett 2005; 579: 1469-1476. (Pubitemid 40289198)
33. Barth S, Nesper J, Hasgall PA, Wirthner R, Nytko KJ, Edlich F et al. The peptidyl prolyl cis/ trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Mol Cell Biol 2007; 27: 3758-3768. (Pubitemid 46726183)
34. Kim BY, Kim H, Cho EJ, Youn HD. Nur77 upregulates HIF-alpha by inhibiting pVHL-mediated degradation. Exp Mol Med 2008; 40: 71-83. (Pubitemid 351346819)
35. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 2007; 25: 207-217. (Pubitemid 46109612)
36. Trisciuoglio D, Iervolino A, Zupi G, Del Bufalo D. Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell 2005; 16: 4153-4162. (Pubitemid 41262885)